The goal of this activity is to provide clinicians with the clinical tools necessary to identify patients with NTM-LD in a timely manner and to offer the most state-of-the art guideline-recommended therapies for an adequate treatment response. Faculty share statistics on the increasing incidence of NTM-LD, patient risk factors for initial infection as well as progression of disease, and reasons for diagnostic delay. Current NTM-LD treatment guidelines are discussed, including the importance of airway clearance. Clinical insights are provided for treating refractory Mycobacterium avium complex lung disease, when is watchful waiting before treatment appropriate, how to manage important adverse effects of therapies, and the vital role for involving patients in their NTM-LD care.
Upon completion of this activity, participants should be better able to:
National Jewish Health
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, New York
Chief, Division of Mycobacterial & Respiratory Infections
National Jewish Health
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources